Form 4 for PCSA Processa Pharmaceuticals, Inc.
Accepted 2021-08-30 00:00:00 ET · period of report 2021-08-26 · accession 0001567619-21-016470 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-08-30 | 2021-08-26 | PCSA | Lin Patrick | Chief Business - Strategy Off | P - Purchase | $6.02 | +4,000 | 422.9K | +1.0% | +$24.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-08-26 | P | A | 4,000 | $6.02 | 422,890 | D | — | — | (F1) The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $5.92 to $6.1099, inclusive. The Reporting Person undertakes to provide, Processa Pharmaceuticals, Inc. (the "Company") any security holder of the Company, or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. |